CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 46 enrolled
Drug / intervention
Faster-acting insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02033239
NCT02033239Phase 1Completed
CompareCT.gov

A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes

Novo Nordisk A/S·interventional·Posted Jan 10, 2014·Updated Jan 18, 2017

In Brief

A Phase 1 clinical trial evaluating Faster-acting insulin aspart and insulin aspart for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 10, 2014
Enrollment StartJan 1, 2014
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.5 years ago

Interventions

Faster-acting insulin aspartdrug

Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).

insulin aspartdrug

Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).